Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a Japan-based clinical-stage biotechnology company focused on developing innovative cancer treatments that target RNA-related abnormalities and other cancer-driving mechanisms. Founded in 2017, the company is dedicated to delivering first-in-class therapies for patients with high unmet medical needs in oncology. Its lead candidate, rogocekib (CTX-712), is being evaluated for the treatment of advanced cancers, while additional programs target pathways such as MALT1, CDK12, and GCN2. Chordia continues to advance its oncology pipeline through clinical development, strategic partnerships, and ongoing research aimed at transforming cancer care.
"Chordia Therapeutics is transforming cancer care through pioneering RNA-targeted therapies and the promising development of rogocekib"
Chordia Therapeutics' lead candidate, rogocekib (CTX-712), is emerging as a promising treatment for difficult-to-treat blood cancers. The oral CLK inhibitor has demonstrated encouraging early clinical results, particularly in AML and high-risk MDS patients, including those with splicing factor mutations. The program has also gained FDA orphan drug designation and progressed into Phase 1/2 studies in the U.S.
Rogocekib (CTX-712)
Mechanism of Action: Clk dual-specificity kinase inhibitors
Drug Class: Small molecules Originator: Takeda Indication: Hematologic malignancies
Rogocekib is an oral inhibitor of CDC2-like kinase (CLK), targeting the RNA splicing process that cancer cells depend on.
Positive Phase 1 Results published in early 2026 demonstrated a tolerable safety profile and a 42.9% overall response rate in patients with relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS).
Leveraging Strategic Partnerships and Financing to Advance Oncology Innovation
Chordia Therapeutics operates as a clinical-stage biotechnology company and does not generate revenue through commercial drug sales. Instead, its business model focuses on discovering and developing novel cancer therapies to the proof-of-concept or early clinical stages before partnering with larger pharmaceutical companies through out-licensing agreements. This strategy enables the company to secure upfront licensing fees, milestone-based payments, and long-term royalty opportunities while avoiding the costs associated with large-scale commercialization.
To support its research and development activities, Chordia relies on a combination of strategic partnerships, venture financing, and public market funding. The company has raised more than $69 million through multiple investment rounds and further strengthened its capital position through its June 2024 IPO on the Tokyo Stock Exchange Growth Market. A notable example of its licensing strategy is the agreement with Ono Pharmaceutical for the CTX-177 program, which provided upfront capital and potential future milestone payments.
Chordia's revenue profile reflects the transaction-driven nature of the biotech licensing model, resulting in irregular revenue recognition based on partnership agreements rather than recurring product sales. The company reported JPY 800 million in revenue in 2021 and JPY 2.5 billion in 2023, primarily driven by licensing-related activities, while recording no revenue in 2020, 2022, 2024, and 2025. Despite these intermittent revenue inflows, Chordia continues to report net losses as it invests heavily in advancing its lead oncology candidate, rogocekib (CTX-712), through clinical development. This financial pattern is typical for pre-commercial biotechnology companies focused on creating long-term value through innovation and strategic collaborations.
"Chordia Therapeutics is building value through innovation, transforming early-stage oncology research into strategic partnerships, licensing opportunities, and long-term growth potential."
Chordia Therapeutics: Advancing a Diverse Oncology Pipeline with CTX-712 at the Forefront
Chordia Therapeutics' pipeline is led by CTX-712, a first-in-class CLK inhibitor being evaluated across multiple oncology indications. The program is currently in Phase 1 development for Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), ovarian cancer, and other solid tumors, with a Phase 1/2 trial ongoing for MDS in the US. Beyond CTX-712, the company is advancing CTX-166, a MALT1 inhibitor for lymphocyte malignancies, in Phase 1, while CTX-439, a CDK12 inhibitor targeting solid cancers, remains in the preclinical stage. Chordia is also expanding its early-stage portfolio with GCN2-targeted and additional undisclosed programs for hematologic malignancies and solid tumors, both currently in discovery-stage development, highlighting a diversified oncology pipeline focused on novel molecular targets.
